Our data suggest 1 model for the multifaceted evolution of resistance, such that RBM10 inactivation, for instance via subclonal mutation, may allow for a fraction of cancer cells to avoid apoptosis and persist during initial targeted therapy, resulting in an incomplete tumor response. Here, RBM10 is linked to cancer.